cAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for inflammatory bowel disease (IBD). Founded by the teams behind Entyvio®, Humira®, Otezla®, and Zeposia®.
Investors 1
| Date | Name | Website |
| 10.07.2026 | Longitude ... | longitudec... |
Mentions in press and media 1
| Date | Title | Description |
| - | cAMPfield Therapeutics | “cAMPfield Therapeutics” |